Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, FiscalAI reports. The business had revenue of $0.49 million for the quarter. Firefly Neuroscience had a negative net margin of 1,740.98% and a negative return on equity of 229.99%.
Firefly Neuroscience Price Performance
NASDAQ:AIFF traded up $0.02 during trading hours on Wednesday, hitting $1.82. 138,283 shares of the company were exchanged, compared to its average volume of 7,196,577. The company’s 50 day moving average price is $1.91 and its 200-day moving average price is $1.49. Firefly Neuroscience has a 52-week low of $0.62 and a 52-week high of $3.77. The stock has a market capitalization of $26.95 million, a price-to-earnings ratio of -1.01 and a beta of 0.60.
Institutional Trading of Firefly Neuroscience
Large investors have recently made changes to their positions in the business. Savvy Advisors Inc. purchased a new stake in shares of Firefly Neuroscience in the 3rd quarter valued at $63,000. Jane Street Group LLC acquired a new position in shares of Firefly Neuroscience in the 4th quarter valued at $53,000. Geode Capital Management LLC raised its position in Firefly Neuroscience by 92.9% during the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after acquiring an additional 58,067 shares during the period. Finally, Vanguard Group Inc. raised its position in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the period. 4.96% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Read Our Latest Analysis on Firefly Neuroscience
Firefly Neuroscience Company Profile
Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.
The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.
Read More
- Five stocks we like better than Firefly Neuroscience
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
